您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8420 处方药 8047 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 日本药房
产地国家: 日本
所属类别: 骨科药物->治疗骨质疏松药物
处方药:处方药
包装规格: 0.5微克/胶囊 100胶囊/盒
计价单位:
  点击放大  
生产厂家中文参考译名:
中外制药株式会社
生产厂家英文名:
Chugai Pharmaceutical Co Ltd
该药品相关信息网址1:
http://www.kegg.jp/medicus-bin/japic_med?japic_code=00059337
该药品相关信息网址2:
http://www.chugai-pharm.co.jp/hc/ss/english/news/detail/20110408110000.html
原产地英文商品名:
EDIROL(エディロールカプセル) 0.5mcg/cap 100caps/box
原产地英文药品名:
ELDECALCITOL
原产地英文化合物名称:
(1R,2R,3R,5Z,7E)-2-(3hydroxiypropyloxy)-9,10-secocholesta-5,7,10(19)triene-1,3,25-triol
中文参考商品译名:
EDIROL(エディロールカプセル) 0.5微克/胶囊 100胶囊/盒
中文参考药品译名:
艾尔骨化醇
原产地国家批准上市年份:
2011/01/21
英文适应病症1:
Osteoporosis
临床试验期:
完成
中文适应病症参考翻译1:
骨质疏松症
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20125222535611.PDF,20125222532417.PDF)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文艾尔骨化醇处方资料(仅供参考)

骨质疏松症治疗药物——艾尔骨化醇
日本厚生省于2011年1月21日批准骨质疏松症治疗药物——艾尔骨化醇上市,其有效物质艾尔骨化醇是继阿法骨化醇后又一新的用于治疗骨质疏松症的活性维生素D3衍生物。一项由1 054例骨质疏松症患者参加的历时3年的Ⅲ期临床数据显示,艾尔骨化醇疗效优于阿法骨化醇,且安全性与阿法骨化醇相似,具有较好的应用前景。

商品名:Edirol(エディロールカプセル)

通用名:艾尔骨化醇(eldecalcitol)

原研公司:日本中外制药株式会社、日本正大制药株式会社

类别:骨质疏松症治疗药(活性维生素D3制剂)

分子式:C30H50O5

相对分子质量:490.71

化学名:(1R,2R,3R,5Z,7E)-2-(3hydroxiypropyloxy)-9,10-secocholesta-5,7,10(19)triene-1,3,25-triol

CAS号:104121-92-8

适应症:骨质疏松症

用法与用量:成人1日1次,每次0.75μg口服。视症状可减少服药剂量。

获批单位:日本中外制药株式会社

批准日期:2011年1月21日

剂型规格:(1)软胶囊,0.5μg;(2)软胶囊,0.75μg

颜色:(1)茶白色不透明;(2)茶褐色透明包装:(1)100片(PTP)、140片(PTP)

Launch of the Osteoporosis Agent “Edirol® Capsule”
April 8, 2011 (Tokyo) - Chugai Pharmaceutical Co., Ltd.[Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, “Chugai”)] and Taisho Toyama Pharmaceutical Co., Ltd.[Head Office: Toshima-ku, Tokyo; President: Akira Ohira (hereafter, “Taisho Toyama”)] announced today that eldecalcitol, an active vitamin D3 agent [brand name: Edirol® Capsule 0.5mg and 0.75mg (hereafter, “Edirol®”)], which obtained approval on January 21, 2011 for the treatment of osteoporosis, has been listed on National Health Insurance drug reimbursement price list on March 11 and will be launched on April 11.
 
It is estimated that 12 million people have osteoporosis in Japan. It is important to increase bone density and thus reduce the incidence of fractures since osteoporosis-related fractures reduce quality of life, rendering patients bedridden and increase the risk of death. Edirol® is an activated vitamin D3 agent which was discovered by Chugai and co-developed with Taisho Pharmaceutical Co., Ltd. [Head Office: Toshima-ku, Tokyo; Chairman and CEO: Akira Uehara]. As an active vitamin D3 agent with an indication of osteoporosis, Edirol® comes to the market as a new treatment after many years since the launch of alfacalcidol (Chugai brand name: Alfarol®, launch: 1981, additional indication of osteoporosis: 1983) and calcitriol (Chugai brand name: Rocaltrol®, launch: 1986, additional indication of osteoporosis: 1989). “Edirol®,” as a new active vitamin D3 derivative that enhances effect to bone, will contribute to significant improvement of the quality of life of the patients.
 
Through the provision of the new treatment options, Chugai and Taisho Toyama will continue its effort to contribute to osteoporosis treatment and to make efforts for promoting the proper use.
 
Note) “Alfarol® Capsule 3mg” and “Rocaltrol® Injection” is not indicated for osteoporosis.

Product name:
Edirol® Capsule 0.5mg
Edirol® Capsule 0.75mg

Generic name:Eldecalcitol
 
Indication:Osteoporosis
 
Dosage and administration: Usually, for adults, 0.75mg of eldecalcitol should be orally administered once daily. However, the dosage may be reduced to 0.5mg once daily according to the symptoms.
 
Date of approval:January 21, 2011
 
Date of drug price listing:March 11, 2011
 
Date of launch:April 11, 2011
 
Shelf life:2 years 6 months
 
Edirol® is a registered trademark of Chugai Pharmaceutical Co., Ltd.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20125222535611.PDF,20125222532417.PDF)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2019-4-2
附件:


20125222535611.PDF    

20125222532417.PDF    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com